Phase 2b/3 Study of T3D-959 for Mild-to-Moderate Alzheimer's Disease
This study is testing an experimental drug called T3D-959 for people with mild-to-moderate Alzheimer's disease. T3D-959 is a small molecule that works by regulating genes involved in how your body uses energy and fats. Researchers want to see if T3D-959 is safe and effective, and if it can help change the course of the disease. You would take T3D-959 or a placebo (an inactive substance) once a day for 78 weeks. To join, you need to be between 50 and 90 years old, have a caregiver, and have a biological diagnosis of Alzheimer's disease confirmed by a plasma biomarker (a test that looks for specific substances in your blood). Success will be measured by changes in your thinking abilities (ADAS-Cog13) and daily living skills (ADCS-iADL) after 78 weeks. The current recruitment status is unclear.
- Study design
- This is a randomized, double-blind, placebo-controlled study with 376 planned participants. Participants will be assigned by chance to receive either T3D-959 or a placebo.
- What's involved
- You would take study medication once daily for 78 weeks. Safety, effectiveness, and other assessments will be evaluated during this time.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for four weeks after the end of the 78-week treatment period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- John Didsbury, Chief Executive Officer, Ph.D · STUDY_DIRECTOR · T3D Therapeutics, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from baseline to end of treatment in ADAS-Cog13 and ADCS-iADL78 weeks
Primary Efficacy Endpoint • Co-primary endpoints of Alzheimer's Disease Assessment Scale cognitive subscale, 13-items (ADAS-Cog13) with a score range of 0-85 (higher scores indicating greater dysfunction) and Alzheimer's Disease Cooperative Study Instrumental Activities of Daily Living (ADCS-iADL) with a score range of 0-56 (lower scores indicating worse performance), in subjects with a clinical diagnosis of mild-to-moderate AD and biological diagnosis of AD pathology. ADAS-cog 13